Wednesday, September 30, 2009

NEW SOUTH AFRICA!

The latest crime statistics showed that about 50 people were murdered in South Africa a day, while business robberies increased by 41.5 percent and house robberies by 27.3 percent.




Please post your support and prayers for Kerryn Roodt


“Kerryn Roodt was robbed and shot while on a week’s holiday down at the coast,” writes her friend Mariette Van Antwerp on :


”Kerryn and her boyfriend came down to the South Coast for a week to have fun and enjoy a week’s holiday,” writes Mrs Van Antwerp, who is from Amanzimtoti, Kwa-Zulu. “They were busy packing when four young men aged between 14 to 17 years climbed over the wall and held them at gunpoint. “They robbed everything they had with them even took their shoes they had on. The attackers told Kerryn they are going to rape her and then “when they are finished with her they are going to rape her boyfriend as well”.


They told him not to look while they are busy raping her as they are going to shoot him if he did. They started licking and kissing her all over her body – but something alarmed them and they went outside as they walked out one said don't shoot, its going to make a noise. But two came back kissed her again and said : “Goodbye my beautiful young white baby” and shot her. They fired a shot at her boyfriend as well but they missed him.


Kerryn now is paralysed and needs all the prayer and support she can get… http://www.blogger.com/'http://www.facebook.com/group.php?gid=


Join Adriana Stuijt at Facebook – and stay informed!


Source: Censor Bugbear (Adriana Stuijt)



For more information visit http://www.dienuwesuidafrika.com

Sunday, September 20, 2009

Thursday, September 17, 2009

Shape-HF™ Cardiopulmonary Testing System




Dean MacCarter, Ph.D. Addressed Differentiation of Responder vs Non-Responder CRT Status with Low Level Exercise at HFSA13th Annual Scientific Meeting


Speaking at the recent Heart Failure Society of America Scientific Meeting, Dr. MacCarter discussed how breathing efficiency measurements during low level exercise may offer a better discriminator for CRT responder and no-responsder outcomes. He also introduced a new objective method for optimizing CRT in heart failure patients using the FDA-approved Shape-HF™ Cardiopulmonary Testing System--the accuracy of which was validated in a recent Mayo Clinic study--to measure changes in patient breathing efficiency as cardiac resynchronization therapy (CRT) pacemaker settings are adjusted. In this way, physicians are able to assess the physiological effect of therapy in real time while the patient is exercising at a level consistent with normal daily activity.


Minneapolis-St. Paul, MN (PRWEB) September 17, 2009 -- Speaking at the recent Heart Failure Society of America 13th Annual Meeting, September 13 to 16, Dean MacCarter, Ph.D., Vice President Clinical Affairs for Shape Medical Systems, Inc., addressed how breathing efficiency measurements during low level exercise may offer a better discriminator for cardiac resynchronization therapy (CRT) responder and non-responder outcomes. He also introduced the audience to a new patented method for optimizing therapy in patients with implanted cardiac resynchronization pacemakers. This new method involves using the FDA-approved Shape-HF™ Cardiopulmonary Testing System (http://www.shapemedsystems.com/products.html)--the accuracy of which was validated in a recent Mayo Clinic study--to measure changes in patient breathing efficiency as CRT pacemaker settings are adjusted. In this way, physicians are able to assess the physiological effect of therapy in real time while the patient is exercising at a level consistent with normal daily activity.


CRT is used in severe cases of heart failure to restore synchrony between the heart chambers during the heartbeat. In patients with advanced heart failure the heart may not beat strongly or efficiently enough to supply adequate oxygen to peripheral tissues (such as active skeletal muscles), and poor blood flow to the lungs disrupts the process of exchanging needed oxygen for carbon dioxide, a waste product of normal metabolism. Combined, these effects lower the amount of oxygen in the blood, which decreases the patient's ability to exercise and causes inefficient, labored breathing."Shortness of breath on even mild exertion is a key symptom in heart failure," says Dr. MacCarter. "We know that a positive response to CRT improves breathing efficiency during exercise, so it makes sense that parameters that can measure patient breathing efficiency can be used to define patient response and determine the proper pacemaker settings for CRT."


The test involves measuring ventilation parameters while the patient exercises on a treadmill at a very low intensity of one mile per hour with the treadmill set at a minimal 1% to 2% grade. "This is a level of exercise that is consistent with normal daily activity in this patient population," notes MacCarter. As the patient exercises at a steady state heart rate, the physician adjusts therapy settings every two minutes, enough time for the adjustments to be reflected in breathing physiology. At the end of the test, during which four to five therapy settings are tested, the Shape-HF™ System uses a proprietary computer algorithm to rank the physiological response to exercise at each setting. The physician then reviews the results and chooses the therapy setting he or she believes is most appropriate for the patient.


"The CRT response rate in heart failure patients is about 70%. By using the Shape-HF™ System, physicians may be able to help the remaining 30%--the non-responders--feel better," says Clarence Johnson, President and COO of Shape Medical Systems. "Because patient breathing efficiency is so sensitive to changes in CRT delay settings, using gas exchange parameters to assess these changes provides a completely objective method for defining response to CRT."


The Shape-HF System is the only device that objectively measures CRT response in real time while the patient is exercising. The System is cost-effective, easy to use, and the test is easy on the patient. "CRT patients generally believe they should spend most of their time lying on the couch," said Dr. MacCarter. "Our objective is to get them off the couch, back on their feet and enjoying life again."


About the Heart Failure Society of America (http://www.hfsa.org/annual_meeting.asp)- The Heart Failure Society of America (HFSA) is a nonprofit educational organization, founded in 1994 as the first organized association of heart failure experts. Today HFSA has over 1,500 members and provides a forum for all those interested in heart function, heart failure research and patient care. The HFSA Annual Scientific Meeting is designed to highlight recent advances in the development of strategies to address the complex epidemiological, clinical and therapeutic issues of heart failure.


About Shape Medical Systems, Inc (http://www.shapemedsystems.com/index.html). - Shape Medical Systems Inc. is a privately held, St. Paul, Minnesota-based medical device company whose core technology lies in the development and commercialization of products for assessing heart/lung interaction and ventilation in chronic heart failure and other cardiopulmonary disease. Shape's clear mission is to develop products that increase the quality of patients' lives by helping doctors quantify shortness of breath, assess patient functional capacity, optimize drug, device and rehabilitation therapy, and monitor patient progress. Shape Medical Systems was founded in 2004 and received FDA market clearance for the Shape-HF™ Cardiopulmonary Testing System in April 2009. The Shape-HF™ System, testing protocols and applications are protected by patent 7,225,022 and other U.S. and foreign patents issued and pending.

Monday, September 14, 2009

Stellenbosch scientists identifies the gene that causes inherited heart disease




(From left standing) Sr Althea Goosen (Stellenbosch University); Prof Olaf Pongs (University of Hamburg); Prof Paul Brink (Stellenbosch University); Dr Lou Hofmeyr (Stellenbosch University). (Front left sitting) Prof Eric Schulze-Bahr (University of Munster); Prof Valerie Corfield (Stellenbosch University).
After a scientific search of more than three decades, researchers in the Faculty of Health Sciences, Stellenbosch University - in collaboration with international partners - have pinpointed the rogue gene that causes the inherited heart disease, known as progressive familial heart block type I, in a group of South African families whose ancestors can all be traced to one immigrant who landed on these shores in 1696.


The disease was first described by Prof Andries Brink - a cardiac specialist and former dean of the Faculty - in 1977. In 1986, Brink's son, Prof Paul Brink, in collaboration with Prof Valerie Corfield - both of the Faculty of Health Sciences - embarked on the search for the genetic mutation that triggers the condition and causes a disruption of the electrical impulses that control heart contractions. They traced this to a small area on chromosome 19 which contained about 80 genes. This search recently came to an end when Brink and Corfield, in collaboration with scientists from Hamburg and Münster in Germany, managed to pinpoint the exact gene amongst this group.


The study, which represents years of research and at times involved teams of other scientists, clinicians, cardiac specialists and technologists of the Stellenbosch Faculty of Health Sciences, is due to be published in the September edition of the international Journal of Clinical Investigation. However, an online version of the article can be accessed ahead of print, on the Journal's website [http://www.jci.org/]


The study of progressive familial heartblock started at Stellenbosch University in the 1970's when Prof Andries Brink - then practicing as a cardiac specialist at the Tygerberg Hospital - treated a baby who was born with a very slow heart rate. The child's condition was so serious that she had to be fitted with an artificial cardiac pacemaker. She thus became the first baby in South Africa to be treated with a pacemaker. According to Prof Paul Brink, it was a big decision to make at the time because artificial pacemakers were at an early stage of development and they were almost the size of a brick. Today, the body of a pacemaker is less than four centimeters long, and it is implanted under the skin with electrodes regulating the beating of the heart.


While Brink was treating the baby, he became aware of another child who also needed a pacemaker. This child happened to be a close relative of the baby under his care. He then examined the mother and found evidence of a similar underlying disease - but not as advanced as that of the baby. This lead Brink to believe that he was dealing with a family problem and he called in the help of Dr Marie Torrington, an expert in the field of genealogical research, who soon traced the disease to other families - most of them living in the Eastern Cape. She found that the carrier of the defective gene came to South Africa from Madeira, Portugal in 1696. He married a woman of Dutch descent. Today, all South Africans affected by progressive familial heart block are descendants of this couple.


Roughly 50% of children born to an affected person will be carriers. Of these "about two thirds will need a pacemaker at one time or another," says Prof Valerie Corfield. "A very small percentage of them will show no evidence of the disease on an electrocardiogram, even though they carry the gene, while others will display an underlying electrical glitch."


According to Prof Paul Brink, progressive familial heart block is characterized by a slow heart rate which necessitates a pacemaker. "The disease can occur any time from birth until old age and in some cases it has been identified in utero. Today it can be managed with the timely implantation of a pacemaker, but before the advent of this device it often claimed the lives of patients affected by the condition."


He says the identification of the affected gene could not have taken place without the ongoing cooperation and interest of the families affected by the disease. At the same time, advances in molecular biology in the 1990's and the mapping of the human genome in particular, made it possible for himself and Corfield to use the information, gathered from large family studies, to pinpoint a particular place on one chromosome where the rogue gene was situated.


However, even with their access to the human genome, "it was like looking for a needle in a haystack. There were at least eighty genes in the area where we expected to find the rogue gene. Examining all of them was a costly and time-consuming process," says Corfield.
"It was during this search that Prof Olaf Pongs of a research team in Hamburg, Germany, contacted us serendipitously and told us that he was interested in a particular gene situated in our search area and that we should take a closer look at this gene. We thus teamed up with Pongs and another research team in Münster, Germany and through our joint efforts it was finally confirmed that the gene that interested Pongs, indeed showed a very small change that leads to the development of the disease. Through our research it soon became clear that the product of this gene was playing a role in the way heart cells handle sodium and potassium, which underlie the electrical signals of the heart."


The discovery of the rogue gene means that families in the affected population can now receive an accurate genetic diagnosis and learn at an early stage which members of a family is at risk of developing the disease - and should be followed up accordingly.


At the same time, it will give scientists and clinicians better insight and understanding of many conditions affecting the electrical system of the heart, such as non-genetic delays in the heart rate which is common in older people.


* Brink and Corfield are also involved in a wide range of studies of other genetic cardiac disorders, most of which also involve founder families of Afrikaner descent, i.e. a cardiac muscle disease known as hypertrophic cardiomyopathy that predisposes people – often young and seemingly healthy sportsmen and women - to sudden unexpected death, as well as a Long QT syndrome which causes dangerously irregular heart rhythms and another conduction disorder, known as progressive familial heart block, type II.